---
title: "Crinetics Shares Edge Up After Vertex Announces $10 Billion Acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292109907.md"
description: "Crinetics edges up 0.3% after-hours to record high as Vertex announces $10B all-cash acquisition at $85/share, deal expected Q3 2026."
datetime: "2026-07-08T20:12:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292109907.md)
  - [en](https://longbridge.com/en/news/292109907.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292109907.md)
---

# Crinetics Shares Edge Up After Vertex Announces $10 Billion Acquisition

Crinetics Pharmaceuticals(CRNX.US) 盘后涨**0.3%**，现报**83.49**美元，股价创新高。

消息面上，Vertex Pharmaceuticals 宣布以约**100 亿**美元现金收购 Crinetics，收购价为每股**85**美元，交易预计于 2026 年第三季度完成。

此次收购将为 Vertex 带来两款内分泌疾病领域药物：已获批的肢端肥大症治疗药物 PALSONIFY，以及处于三期临床阶段的先天性肾上腺皮质增生症候选药物 Atumelnant。

### Related Stocks

- [CRNX.US](https://longbridge.com/en/quote/CRNX.US.md)

## Related News & Research

- [CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030](https://longbridge.com/en/news/293389069.md)
- [Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans](https://longbridge.com/en/news/293268909.md)
- [Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/293376066.md)
- [JonesTrading Reiterates Hold Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX)](https://longbridge.com/en/news/291960986.md)
- [Crinetics director Vivaldi Coelho Rogerio sells 3,000 shares for $120,000](https://longbridge.com/en/news/291974814.md)